<DOC>
	<DOCNO>NCT00963937</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety range dose oral sumatriptan acute treatment migraine child age 10 17 .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Oral Sumatriptan Acute Treatment Migraine Children Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Subject &gt; 10 year age &lt; 17 year age inform consent Randomization Visit . Subject migraine without aura ( ICHDII criterion , 1.1 1.2.1 ) . A minimum six month history migraine prior entry study require . Subject history least two , eight , attack per month two month prior entry study . All migraine attack associate 3 pain 5grade scale last minimum three hour two month prior entry study . Subject show nonresponse least one NSAIDs acetaminophen two month prior entry study . Subject able distinguish migraine headache ( e.g. , tensiontype headache ) . Subject able read , comprehend , complete subject diary . Males female subject . Female subject eligible participation study one follow Females nonchildbearing potential ( i.e. , physiologically incapable become pregnant undergone female sterilization ) Females childbearing potential , negative pregnancy test Screening Visit , agree use one follow GlaxoSmithKline ( GSK ) specify highly effective method avoid pregnancy : Abstinence Oral Contraceptive , either combined progestogen alone Male partner sterilization ( vasectomy documentation azoospermia ) prior female subject 's entry study , male sole partner subject ) Double barrier method : condom occlusive cap ( diaphragm cervical/vault cap ) plus spermicidal agent ( foam/gel/film/cream/suppository ) Subject 's parent legal guardian willing able provide inform consent prior subject entry study . Subject willing able provide inform assent prior entry study . Subjects consider enrolment must QTc ( either QTc B ( Bazett 's correction ) QTc F ( Fridericia 's correction ) ) &lt; 450msec Screening Visit , exception subject bundle branch block ( either QTc B QTc F must &lt; 480msec ) . Note : For purpose criterion , QTc B define ( QT interval msec ) / ( square root RR interval second ) ; QTc F define ( QT interval msec ) / ( cube root RR interval second ) . ) Liver function test Screening Visit : AST ALT &lt; 2xULN ; alkaline phosphatase total bilirubin &lt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) Subject &lt; 30 kg . Subject 15 headache day per month total ( migraine , probable migraine , tensiontype ) . Subject retinal ( ICHDII 1.4 ) , basilar ( ICHDII 1.2.6 ) , hemiplegic ( ICHDII 1.2.4 1.2.5 ) , Ophthalmoplegic migraine ( ICHDII 13.17 ) . Subject secondary headache . Subject history cerebrovascular disease ischemic cerebrovascular disease . Subject history myocardial infarction . Subject uncontrolled hypertension . Subject symptom sign ischemic cardiac syndrome . Subject variant angina . Subject evidence peripheral vascular syndrome . Subject evidence history epilepsy structural brain lesion lower convulsive threshold , treat antiepileptic drug seizure control . Subject history impair hepatic renal function , investigator ( subinvestigator ) 's opinion , contraindicate participation study . Subject unstable liver disease ( define presence ascites , encephalopathy , coagulopathy , hypoalbuminaemia , esophageal gastric varix persistent jaundice ) . Subject cirrhosis . Subject know biliary abnormality ( exception Gilberts 's syndrome asymptomatic gallstone ) . Subject hypersensitivity , allergy , intolerance , contraindication use triptan ( include sumatriptan preparation ) sulfonamide compound . Subject use ergot medication previous three month migraine prophylaxis take medication stabilize ( i.e. , change dose within past 2 month ) either chronic intermittent migraine prophylaxis . Subject take , plan take , monoamine oxidase inhibitor ( MAOI ) anytime within two week prior entry study . Subject evidence psychotropic , alcohol , substance abuse within last year . Subject participate investigational drug trial within previous 3 month plan participate another study time study . Subject concurrent medical psychiatric condition , investigator ( subinvestigator ) 's judgment , contraindicate participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>adolescent</keyword>
	<keyword>sumatriptan</keyword>
	<keyword>child</keyword>
	<keyword>migraine</keyword>
</DOC>